{
  "symbol": "BFRI",
  "company_name": "Biofrontera Inc",
  "ir_website": "https://investors.biofrontera-us.com/",
  "structured_data": [
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Q3 2024 Financial Results",
          "url": "https://investors.biofrontera-us.com/financial-reports/#q3_2024_results",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# Financial Reports\n\n## Annual Reports\n\nThere are no items to display at this time.\n\n## [Jul 12th, 2021 ](#)\n\n## [2nd Quarterly Reports](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n## [Annual Report 2023](#)\n\n## [Fourth Quarter and Full Year 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-K.pdf)\n\n## [Annual Report 2021](#)\n\n## [Fourth Quarter and Full Year 2021 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/04/AnnualReport2021_BFRI.pdf)\n\n## Quarterly Reports\n\nThere are no items to display at this time.\n\n## [Q2 2024](#)\n\n## [Second Quarter 2024 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://app.quotemedia.com/data/downloadFiling?webmasterId=104270&ref=318523972&type=HTML&symbol=BFRI&cdn=6102d3b0e47b041b13dcfd7a0c9cf392&companyName=Biofrontera+Inc.&formType=10-Q&formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&dateFiled=2024-08-14)\n\n## [Q1 2024](#)\n\n## [First Quarter 2024 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-Q-1.pdf)\n\n## [Jul 12th, 2021 ](#)\n\n## [2nd Quarterly Reports](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n## Proxy Material \n\nThere are no items to display at this time.\n\n## [DEFR-14A](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/DEFR-14A.pdf)\n\n## [DEF-14A](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/FormDEF14A.pdf)\n\n## Archive Financial Reports \n\nThere are no items to display at this time.\n\nFinancial reports 2021\n\n[Annual report 2021](#)\n\n[Quarterly report Q3 2021](#)\n\n[Half-Year report 2021](#)\n\n[Quarterly report Q1 2021](#)\n\n## [Q3 2023](#)\n\n## [Third Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-Q.pdf)\n\n## [Q2 2023](#)\n\n## [Second Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/08/Q2-2023.pdf)\n\n## [Q1 2023](#)\n\n## [First Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/08/Q1-2023.pdf)\n\n## [Annual Report 2022](#)\n\n## [Fourth Quarter and Full Year 2022 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/04/BFRI-Annual_report_pursuant_to_Section_13or15d-10-K2023-03-13.pdf)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        },
        {
          "title": "Q2 2024 Financial Results",
          "url": "https://investors.biofrontera-us.com/financial-reports/#q2_2024_results",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# Financial Reports\n\n## Annual Reports\n\nThere are no items to display at this time.\n\n## [Jul 12th, 2021 ](#)\n\n## [2nd Quarterly Reports](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n## [Annual Report 2023](#)\n\n## [Fourth Quarter and Full Year 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-K.pdf)\n\n## [Annual Report 2021](#)\n\n## [Fourth Quarter and Full Year 2021 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/04/AnnualReport2021_BFRI.pdf)\n\n## Quarterly Reports\n\nThere are no items to display at this time.\n\n## [Q2 2024](#)\n\n## [Second Quarter 2024 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://app.quotemedia.com/data/downloadFiling?webmasterId=104270&ref=318523972&type=HTML&symbol=BFRI&cdn=6102d3b0e47b041b13dcfd7a0c9cf392&companyName=Biofrontera+Inc.&formType=10-Q&formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&dateFiled=2024-08-14)\n\n## [Q1 2024](#)\n\n## [First Quarter 2024 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-Q-1.pdf)\n\n## [Jul 12th, 2021 ](#)\n\n## [2nd Quarterly Reports](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n## Proxy Material \n\nThere are no items to display at this time.\n\n## [DEFR-14A](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/DEFR-14A.pdf)\n\n## [DEF-14A](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/FormDEF14A.pdf)\n\n## Archive Financial Reports \n\nThere are no items to display at this time.\n\nFinancial reports 2021\n\n[Annual report 2021](#)\n\n[Quarterly report Q3 2021](#)\n\n[Half-Year report 2021](#)\n\n[Quarterly report Q1 2021](#)\n\n## [Q3 2023](#)\n\n## [Third Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-Q.pdf)\n\n## [Q2 2023](#)\n\n## [Second Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/08/Q2-2023.pdf)\n\n## [Q1 2023](#)\n\n## [First Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/08/Q1-2023.pdf)\n\n## [Annual Report 2022](#)\n\n## [Fourth Quarter and Full Year 2022 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/04/BFRI-Annual_report_pursuant_to_Section_13or15d-10-K2023-03-13.pdf)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        },
        {
          "title": "Q1 2024 Financial Results",
          "url": "https://investors.biofrontera-us.com/financial-reports/#q1_2024_results",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# Financial Reports\n\n## Annual Reports\n\nThere are no items to display at this time.\n\n## [Jul 12th, 2021 ](#)\n\n## [2nd Quarterly Reports](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n## [Annual Report 2023](#)\n\n## [Fourth Quarter and Full Year 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-K.pdf)\n\n## [Annual Report 2021](#)\n\n## [Fourth Quarter and Full Year 2021 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/04/AnnualReport2021_BFRI.pdf)\n\n## Quarterly Reports\n\nThere are no items to display at this time.\n\n## [Q2 2024](#)\n\n## [Second Quarter 2024 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://app.quotemedia.com/data/downloadFiling?webmasterId=104270&ref=318523972&type=HTML&symbol=BFRI&cdn=6102d3b0e47b041b13dcfd7a0c9cf392&companyName=Biofrontera+Inc.&formType=10-Q&formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&dateFiled=2024-08-14)\n\n## [Q1 2024](#)\n\n## [First Quarter 2024 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-Q-1.pdf)\n\n## [Jul 12th, 2021 ](#)\n\n## [2nd Quarterly Reports](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n## Proxy Material \n\nThere are no items to display at this time.\n\n## [DEFR-14A](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/DEFR-14A.pdf)\n\n## [DEF-14A](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/FormDEF14A.pdf)\n\n## Archive Financial Reports \n\nThere are no items to display at this time.\n\nFinancial reports 2021\n\n[Annual report 2021](#)\n\n[Quarterly report Q3 2021](#)\n\n[Half-Year report 2021](#)\n\n[Quarterly report Q1 2021](#)\n\n## [Q3 2023](#)\n\n## [Third Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2024/05/Form10-Q.pdf)\n\n## [Q2 2023](#)\n\n## [Second Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/08/Q2-2023.pdf)\n\n## [Q1 2023](#)\n\n## [First Quarter 2023 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/08/Q1-2023.pdf)\n\n## [Annual Report 2022](#)\n\n## [Fourth Quarter and Full Year 2022 Financial Results](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2023/04/BFRI-Annual_report_pursuant_to_Section_13or15d-10-K2023-03-13.pdf)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        }
      ]
    },
    {
      "section_name": "News Releases",
      "links": [
        {
          "title": "Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note",
          "url": "https://investors.biofrontera-us.com/news-events/#price_note",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# News & Events\n\n## News and Media\n\nThere are no items to display at this time.\n\n## Events\n\n## [Date ](#)\n\n## [Event Title](#)\n\n## [Event ](#)\n\n## [When ](#)\n\n## [Where](#)\n\n## Special Meeting of Stockholders\n\n## Monday, May 22, 2023 at 9:00 AM, Eastern Time\n\nVirtual Meeting :<https://web.viewproxy.com/bfri/2023>\n\n## 35th Annual Roth Conference\n\n## March 12-14, 2023\n\nWebcast :[https://www.webcaster4.com/Webcast/Page/2952/47627](https://wsw.com/webcast/roth46/register.aspx?conf=roth46&page=b8f.de&url=https://wsw.com/webcast/roth46/b8f.de/1934305)\n\n## 33rd Annual Roth Conference\n\n## March 13-14, 2023\n\nLaguna Nigel, CA \n\n## Fourth Quarter and Full Year 2022 Financial Results Conference Call\n\n## Wednesday, March 8, 2023 at 4:30PM ET\n\nDial in:Toll Free: [888-506-0062](tel:8885060062)\n\nInternational: [973-528-0011](tel:9735280011)\n\nAccess Code: 990014\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2948/47545>\n\n## MicroCap Rodeo Best Ideas Virtual Conference\n\n## February 21, 2023, 10:00 AM Eastern Time\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2952/47627>\n\n## LHA Offsite during J.P. Morgan\n\n## Monday, January 9, 2023 â Wednesday, January 11, 2023\n\nSan Francisco, CA \n\n## Annual Meeting\n\n## Monday, December 12, 2022, 9:00 AM Eastern Time\n\nVirtual meeting\n\nStream of the event:\n\n[https://streamstudio.world-television.com/1263-2500-34015/en](https://streamstudio.world-television.com/CCUIv3/frameset.aspx?ticket=1263-2500-34015&target=en-default-&status=ondemand&browser=ns-0-1-0-0-0&stream=html5-video-1000)\n\nAudio of the event:\n\n[https://fileshare.world-television.com/url/b3wbgkxbe2zgcmpv](https://fileshare.world-television.com/ui/core/index.html?mode=single&path=/SHARED/%215bp9s0q6CJLbzfg5FKU7liReoGGOlQbyxBGhmNvr8pNW9Q4Z4tq1o3ssqVdBskW40AoTJs1T3ZdTQ/qlK8I4vrOqQigfUv&shareto=#/)\n\n## Benchmarkâs 11th Annual Discovery One-on-One Investor Conference\n\n## Thursday, December 1, 2022\n\nNew York, NY \n\n## A.G.P.âs Biotech Conference\n\n## Wednesday, November 30, 2022\n\nVirtual Conference \n\n## Third Quarter 2022 Financial Results and Business Update Conference Call\n\n## Monday, November 14, 2022, 11:00 AM Eastern Time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast :Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=igCYZUkD)\n\n## LD Micro Main Event XV\n\n## Wednesday, October 26, 2022, 4:00 PM Pacific Time (7:00 PM Eastern Time)\n\nLuxe Sunset Boulevard Hotel, Los Angeles, CA\n\nWebcast : [https://me22.sequireevents.com](https://me22.sequireevents.com/)\n\n## Second Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, August 12, 2022, 11:00 AM Eastern time \n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast: Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=7OzYdyj8)\n\n## First Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, May 13, 2022, 11:00 AM Eastern time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Q4 and FY 2021 Earnings Call\n\n## Friday, April 8, 2022 Time: 11:00 AM ET\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Third Quarter Earnings Call\n\n## Nov 30, 2021 at 04:30 PM ET \n\nConference call:[1-866-524-3160](tel:18665243160) (toll free)\n\n[1-412-317-6760](tel:14123176760) (international)\n\n## [July 13, 2021 9:00 AM EDT](#)\n\n## [Event ](#)\n\n  * [ Click here for Details ](#)\n\n\n\n## Presentations & Shareholder Letters\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2022/10/BFRI_Renmarkfinancial.jpg) ](https://www.renmarkfinancial.com/vndrs/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-10-14)\n\n## [Jan 18th, 2022 ](#)\n\n## [Shareholder Letter 2022](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/01/20220118_BFRI-Shareholder-Letter-final.pdf)\n\n## [Jan 18th, 2022 ](#)\n\n## [Presentation](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        },
        {
          "title": "Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update",
          "url": "https://investors.biofrontera-us.com/news-events/#q3_2024_update",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# News & Events\n\n## News and Media\n\nThere are no items to display at this time.\n\n## Events\n\n## [Date ](#)\n\n## [Event Title](#)\n\n## [Event ](#)\n\n## [When ](#)\n\n## [Where](#)\n\n## Special Meeting of Stockholders\n\n## Monday, May 22, 2023 at 9:00 AM, Eastern Time\n\nVirtual Meeting :<https://web.viewproxy.com/bfri/2023>\n\n## 35th Annual Roth Conference\n\n## March 12-14, 2023\n\nWebcast :[https://www.webcaster4.com/Webcast/Page/2952/47627](https://wsw.com/webcast/roth46/register.aspx?conf=roth46&page=b8f.de&url=https://wsw.com/webcast/roth46/b8f.de/1934305)\n\n## 33rd Annual Roth Conference\n\n## March 13-14, 2023\n\nLaguna Nigel, CA \n\n## Fourth Quarter and Full Year 2022 Financial Results Conference Call\n\n## Wednesday, March 8, 2023 at 4:30PM ET\n\nDial in:Toll Free: [888-506-0062](tel:8885060062)\n\nInternational: [973-528-0011](tel:9735280011)\n\nAccess Code: 990014\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2948/47545>\n\n## MicroCap Rodeo Best Ideas Virtual Conference\n\n## February 21, 2023, 10:00 AM Eastern Time\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2952/47627>\n\n## LHA Offsite during J.P. Morgan\n\n## Monday, January 9, 2023 â Wednesday, January 11, 2023\n\nSan Francisco, CA \n\n## Annual Meeting\n\n## Monday, December 12, 2022, 9:00 AM Eastern Time\n\nVirtual meeting\n\nStream of the event:\n\n[https://streamstudio.world-television.com/1263-2500-34015/en](https://streamstudio.world-television.com/CCUIv3/frameset.aspx?ticket=1263-2500-34015&target=en-default-&status=ondemand&browser=ns-0-1-0-0-0&stream=html5-video-1000)\n\nAudio of the event:\n\n[https://fileshare.world-television.com/url/b3wbgkxbe2zgcmpv](https://fileshare.world-television.com/ui/core/index.html?mode=single&path=/SHARED/%215bp9s0q6CJLbzfg5FKU7liReoGGOlQbyxBGhmNvr8pNW9Q4Z4tq1o3ssqVdBskW40AoTJs1T3ZdTQ/qlK8I4vrOqQigfUv&shareto=#/)\n\n## Benchmarkâs 11th Annual Discovery One-on-One Investor Conference\n\n## Thursday, December 1, 2022\n\nNew York, NY \n\n## A.G.P.âs Biotech Conference\n\n## Wednesday, November 30, 2022\n\nVirtual Conference \n\n## Third Quarter 2022 Financial Results and Business Update Conference Call\n\n## Monday, November 14, 2022, 11:00 AM Eastern Time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast :Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=igCYZUkD)\n\n## LD Micro Main Event XV\n\n## Wednesday, October 26, 2022, 4:00 PM Pacific Time (7:00 PM Eastern Time)\n\nLuxe Sunset Boulevard Hotel, Los Angeles, CA\n\nWebcast : [https://me22.sequireevents.com](https://me22.sequireevents.com/)\n\n## Second Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, August 12, 2022, 11:00 AM Eastern time \n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast: Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=7OzYdyj8)\n\n## First Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, May 13, 2022, 11:00 AM Eastern time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Q4 and FY 2021 Earnings Call\n\n## Friday, April 8, 2022 Time: 11:00 AM ET\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Third Quarter Earnings Call\n\n## Nov 30, 2021 at 04:30 PM ET \n\nConference call:[1-866-524-3160](tel:18665243160) (toll free)\n\n[1-412-317-6760](tel:14123176760) (international)\n\n## [July 13, 2021 9:00 AM EDT](#)\n\n## [Event ](#)\n\n  * [ Click here for Details ](#)\n\n\n\n## Presentations & Shareholder Letters\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2022/10/BFRI_Renmarkfinancial.jpg) ](https://www.renmarkfinancial.com/vndrs/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-10-14)\n\n## [Jan 18th, 2022 ](#)\n\n## [Shareholder Letter 2022](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/01/20220118_BFRI-Shareholder-Letter-final.pdf)\n\n## [Jan 18th, 2022 ](#)\n\n## [Presentation](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        },
        {
          "title": "Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024",
          "url": "https://investors.biofrontera-us.com/news-events/#results_announcement",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# News & Events\n\n## News and Media\n\nThere are no items to display at this time.\n\n## Events\n\n## [Date ](#)\n\n## [Event Title](#)\n\n## [Event ](#)\n\n## [When ](#)\n\n## [Where](#)\n\n## Special Meeting of Stockholders\n\n## Monday, May 22, 2023 at 9:00 AM, Eastern Time\n\nVirtual Meeting :<https://web.viewproxy.com/bfri/2023>\n\n## 35th Annual Roth Conference\n\n## March 12-14, 2023\n\nWebcast :[https://www.webcaster4.com/Webcast/Page/2952/47627](https://wsw.com/webcast/roth46/register.aspx?conf=roth46&page=b8f.de&url=https://wsw.com/webcast/roth46/b8f.de/1934305)\n\n## 33rd Annual Roth Conference\n\n## March 13-14, 2023\n\nLaguna Nigel, CA \n\n## Fourth Quarter and Full Year 2022 Financial Results Conference Call\n\n## Wednesday, March 8, 2023 at 4:30PM ET\n\nDial in:Toll Free: [888-506-0062](tel:8885060062)\n\nInternational: [973-528-0011](tel:9735280011)\n\nAccess Code: 990014\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2948/47545>\n\n## MicroCap Rodeo Best Ideas Virtual Conference\n\n## February 21, 2023, 10:00 AM Eastern Time\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2952/47627>\n\n## LHA Offsite during J.P. Morgan\n\n## Monday, January 9, 2023 â Wednesday, January 11, 2023\n\nSan Francisco, CA \n\n## Annual Meeting\n\n## Monday, December 12, 2022, 9:00 AM Eastern Time\n\nVirtual meeting\n\nStream of the event:\n\n[https://streamstudio.world-television.com/1263-2500-34015/en](https://streamstudio.world-television.com/CCUIv3/frameset.aspx?ticket=1263-2500-34015&target=en-default-&status=ondemand&browser=ns-0-1-0-0-0&stream=html5-video-1000)\n\nAudio of the event:\n\n[https://fileshare.world-television.com/url/b3wbgkxbe2zgcmpv](https://fileshare.world-television.com/ui/core/index.html?mode=single&path=/SHARED/%215bp9s0q6CJLbzfg5FKU7liReoGGOlQbyxBGhmNvr8pNW9Q4Z4tq1o3ssqVdBskW40AoTJs1T3ZdTQ/qlK8I4vrOqQigfUv&shareto=#/)\n\n## Benchmarkâs 11th Annual Discovery One-on-One Investor Conference\n\n## Thursday, December 1, 2022\n\nNew York, NY \n\n## A.G.P.âs Biotech Conference\n\n## Wednesday, November 30, 2022\n\nVirtual Conference \n\n## Third Quarter 2022 Financial Results and Business Update Conference Call\n\n## Monday, November 14, 2022, 11:00 AM Eastern Time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast :Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=igCYZUkD)\n\n## LD Micro Main Event XV\n\n## Wednesday, October 26, 2022, 4:00 PM Pacific Time (7:00 PM Eastern Time)\n\nLuxe Sunset Boulevard Hotel, Los Angeles, CA\n\nWebcast : [https://me22.sequireevents.com](https://me22.sequireevents.com/)\n\n## Second Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, August 12, 2022, 11:00 AM Eastern time \n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast: Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=7OzYdyj8)\n\n## First Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, May 13, 2022, 11:00 AM Eastern time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Q4 and FY 2021 Earnings Call\n\n## Friday, April 8, 2022 Time: 11:00 AM ET\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Third Quarter Earnings Call\n\n## Nov 30, 2021 at 04:30 PM ET \n\nConference call:[1-866-524-3160](tel:18665243160) (toll free)\n\n[1-412-317-6760](tel:14123176760) (international)\n\n## [July 13, 2021 9:00 AM EDT](#)\n\n## [Event ](#)\n\n  * [ Click here for Details ](#)\n\n\n\n## Presentations & Shareholder Letters\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2022/10/BFRI_Renmarkfinancial.jpg) ](https://www.renmarkfinancial.com/vndrs/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-10-14)\n\n## [Jan 18th, 2022 ](#)\n\n## [Shareholder Letter 2022](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/01/20220118_BFRI-Shareholder-Letter-final.pdf)\n\n## [Jan 18th, 2022 ](#)\n\n## [Presentation](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        },
        {
          "title": "Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of AmeluzÂ®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)",
          "url": "https://investors.biofrontera-us.com/news-events/#study_significance",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# News & Events\n\n## News and Media\n\nThere are no items to display at this time.\n\n## Events\n\n## [Date ](#)\n\n## [Event Title](#)\n\n## [Event ](#)\n\n## [When ](#)\n\n## [Where](#)\n\n## Special Meeting of Stockholders\n\n## Monday, May 22, 2023 at 9:00 AM, Eastern Time\n\nVirtual Meeting :<https://web.viewproxy.com/bfri/2023>\n\n## 35th Annual Roth Conference\n\n## March 12-14, 2023\n\nWebcast :[https://www.webcaster4.com/Webcast/Page/2952/47627](https://wsw.com/webcast/roth46/register.aspx?conf=roth46&page=b8f.de&url=https://wsw.com/webcast/roth46/b8f.de/1934305)\n\n## 33rd Annual Roth Conference\n\n## March 13-14, 2023\n\nLaguna Nigel, CA \n\n## Fourth Quarter and Full Year 2022 Financial Results Conference Call\n\n## Wednesday, March 8, 2023 at 4:30PM ET\n\nDial in:Toll Free: [888-506-0062](tel:8885060062)\n\nInternational: [973-528-0011](tel:9735280011)\n\nAccess Code: 990014\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2948/47545>\n\n## MicroCap Rodeo Best Ideas Virtual Conference\n\n## February 21, 2023, 10:00 AM Eastern Time\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2952/47627>\n\n## LHA Offsite during J.P. Morgan\n\n## Monday, January 9, 2023 â Wednesday, January 11, 2023\n\nSan Francisco, CA \n\n## Annual Meeting\n\n## Monday, December 12, 2022, 9:00 AM Eastern Time\n\nVirtual meeting\n\nStream of the event:\n\n[https://streamstudio.world-television.com/1263-2500-34015/en](https://streamstudio.world-television.com/CCUIv3/frameset.aspx?ticket=1263-2500-34015&target=en-default-&status=ondemand&browser=ns-0-1-0-0-0&stream=html5-video-1000)\n\nAudio of the event:\n\n[https://fileshare.world-television.com/url/b3wbgkxbe2zgcmpv](https://fileshare.world-television.com/ui/core/index.html?mode=single&path=/SHARED/%215bp9s0q6CJLbzfg5FKU7liReoGGOlQbyxBGhmNvr8pNW9Q4Z4tq1o3ssqVdBskW40AoTJs1T3ZdTQ/qlK8I4vrOqQigfUv&shareto=#/)\n\n## Benchmarkâs 11th Annual Discovery One-on-One Investor Conference\n\n## Thursday, December 1, 2022\n\nNew York, NY \n\n## A.G.P.âs Biotech Conference\n\n## Wednesday, November 30, 2022\n\nVirtual Conference \n\n## Third Quarter 2022 Financial Results and Business Update Conference Call\n\n## Monday, November 14, 2022, 11:00 AM Eastern Time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast :Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=igCYZUkD)\n\n## LD Micro Main Event XV\n\n## Wednesday, October 26, 2022, 4:00 PM Pacific Time (7:00 PM Eastern Time)\n\nLuxe Sunset Boulevard Hotel, Los Angeles, CA\n\nWebcast : [https://me22.sequireevents.com](https://me22.sequireevents.com/)\n\n## Second Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, August 12, 2022, 11:00 AM Eastern time \n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast: Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=7OzYdyj8)\n\n## First Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, May 13, 2022, 11:00 AM Eastern time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Q4 and FY 2021 Earnings Call\n\n## Friday, April 8, 2022 Time: 11:00 AM ET\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Third Quarter Earnings Call\n\n## Nov 30, 2021 at 04:30 PM ET \n\nConference call:[1-866-524-3160](tel:18665243160) (toll free)\n\n[1-412-317-6760](tel:14123176760) (international)\n\n## [July 13, 2021 9:00 AM EDT](#)\n\n## [Event ](#)\n\n  * [ Click here for Details ](#)\n\n\n\n## Presentations & Shareholder Letters\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2022/10/BFRI_Renmarkfinancial.jpg) ](https://www.renmarkfinancial.com/vndrs/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-10-14)\n\n## [Jan 18th, 2022 ](#)\n\n## [Shareholder Letter 2022](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/01/20220118_BFRI-Shareholder-Letter-final.pdf)\n\n## [Jan 18th, 2022 ](#)\n\n## [Presentation](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        },
        {
          "title": "Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of AmeluzÂ®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)",
          "url": "https://investors.biofrontera-us.com/news-events/#study_database_lock",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# News & Events\n\n## News and Media\n\nThere are no items to display at this time.\n\n## Events\n\n## [Date ](#)\n\n## [Event Title](#)\n\n## [Event ](#)\n\n## [When ](#)\n\n## [Where](#)\n\n## Special Meeting of Stockholders\n\n## Monday, May 22, 2023 at 9:00 AM, Eastern Time\n\nVirtual Meeting :<https://web.viewproxy.com/bfri/2023>\n\n## 35th Annual Roth Conference\n\n## March 12-14, 2023\n\nWebcast :[https://www.webcaster4.com/Webcast/Page/2952/47627](https://wsw.com/webcast/roth46/register.aspx?conf=roth46&page=b8f.de&url=https://wsw.com/webcast/roth46/b8f.de/1934305)\n\n## 33rd Annual Roth Conference\n\n## March 13-14, 2023\n\nLaguna Nigel, CA \n\n## Fourth Quarter and Full Year 2022 Financial Results Conference Call\n\n## Wednesday, March 8, 2023 at 4:30PM ET\n\nDial in:Toll Free: [888-506-0062](tel:8885060062)\n\nInternational: [973-528-0011](tel:9735280011)\n\nAccess Code: 990014\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2948/47545>\n\n## MicroCap Rodeo Best Ideas Virtual Conference\n\n## February 21, 2023, 10:00 AM Eastern Time\n\nWebcast : <https://www.webcaster4.com/Webcast/Page/2952/47627>\n\n## LHA Offsite during J.P. Morgan\n\n## Monday, January 9, 2023 â Wednesday, January 11, 2023\n\nSan Francisco, CA \n\n## Annual Meeting\n\n## Monday, December 12, 2022, 9:00 AM Eastern Time\n\nVirtual meeting\n\nStream of the event:\n\n[https://streamstudio.world-television.com/1263-2500-34015/en](https://streamstudio.world-television.com/CCUIv3/frameset.aspx?ticket=1263-2500-34015&target=en-default-&status=ondemand&browser=ns-0-1-0-0-0&stream=html5-video-1000)\n\nAudio of the event:\n\n[https://fileshare.world-television.com/url/b3wbgkxbe2zgcmpv](https://fileshare.world-television.com/ui/core/index.html?mode=single&path=/SHARED/%215bp9s0q6CJLbzfg5FKU7liReoGGOlQbyxBGhmNvr8pNW9Q4Z4tq1o3ssqVdBskW40AoTJs1T3ZdTQ/qlK8I4vrOqQigfUv&shareto=#/)\n\n## Benchmarkâs 11th Annual Discovery One-on-One Investor Conference\n\n## Thursday, December 1, 2022\n\nNew York, NY \n\n## A.G.P.âs Biotech Conference\n\n## Wednesday, November 30, 2022\n\nVirtual Conference \n\n## Third Quarter 2022 Financial Results and Business Update Conference Call\n\n## Monday, November 14, 2022, 11:00 AM Eastern Time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast :Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=igCYZUkD)\n\n## LD Micro Main Event XV\n\n## Wednesday, October 26, 2022, 4:00 PM Pacific Time (7:00 PM Eastern Time)\n\nLuxe Sunset Boulevard Hotel, Los Angeles, CA\n\nWebcast : [https://me22.sequireevents.com](https://me22.sequireevents.com/)\n\n## Second Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, August 12, 2022, 11:00 AM Eastern time \n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\nWebcast: Live and 90-day replay webcast are available [here](https://event.choruscall.com/mediaframe/webcast.html?webcastid=7OzYdyj8)\n\n## First Quarter 2022 Financial Results and Business Update Conference Call\n\n## Friday, May 13, 2022, 11:00 AM Eastern time\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Q4 and FY 2021 Earnings Call\n\n## Friday, April 8, 2022 Time: 11:00 AM ET\n\nConference call:[1-877-877-1275](tel:18778771275) (U.S.)\n\n[1-412-858-5202](tel:14128585202) (international)\n\n## Third Quarter Earnings Call\n\n## Nov 30, 2021 at 04:30 PM ET \n\nConference call:[1-866-524-3160](tel:18665243160) (toll free)\n\n[1-412-317-6760](tel:14123176760) (international)\n\n## [July 13, 2021 9:00 AM EDT](#)\n\n## [Event ](#)\n\n  * [ Click here for Details ](#)\n\n\n\n## Presentations & Shareholder Letters\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2022/10/BFRI_Renmarkfinancial.jpg) ](https://www.renmarkfinancial.com/vndrs/renmark-virtual-non-deal-roadshow-nasdaq-bfri-2022-10-14)\n\n## [Jan 18th, 2022 ](#)\n\n## [Shareholder Letter 2022](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](https://investors.biofrontera-us.com/wp-content/uploads/2022/01/20220118_BFRI-Shareholder-Letter-final.pdf)\n\n## [Jan 18th, 2022 ](#)\n\n## [Presentation](#)\n\n[ ![pdf](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/pdf-peg8pj12ldh98do6h4ysjvv3evom2yzdv1r6nkylbs.png) ](#)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filing 2024",
          "url": "https://investors.biofrontera-us.com/sec-filings/#2024",
          "content": "[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Home](https://www.biofrontera-us.com/)\n  * [About us](https://www.biofrontera-us.com/about-us/mission)Open menu\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n    * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n  * [Products](https://www.biofrontera-us.com/products/portfolio)Open menu\n    * [Product Portfolio](https://www.biofrontera-us.com/products/portfolio)\n  * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n  * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)Open menu\n    * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n    * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n  * [Investors](https://investors.biofrontera-us.com/)Open menu\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n  * [Contact](https://www.biofrontera-us.com/contact)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo.png) ](https://investors.biofrontera-us.com)\n\nX\n\n[ ![logo-biofrontera](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-biofrontera-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb68.png) ](https://www.biofrontera-us.com/)\n\n  * [Corporate Menu](#)Open menu\n    * [Home](https://www.biofrontera-us.com/)\n    * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [About us](https://www.biofrontera-us.com/about-us/mission)\n      * [Leadership](https://www.biofrontera-us.com/about-us/leadership)\n    * [Products](https://www.biofrontera-us.com/products/portfolio)\n      * [Portfolio](https://www.biofrontera-us.com/products/portfolio)\n    * [Research](https://www.biofrontera-us.com/research/product-pipeline)\n    * [Career](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Who are the people of Biofrontera?](https://www.biofrontera-us.com/career/who-are-the-people-of-biofrontera)\n      * [Job openings](https://www.biofrontera-us.com/career/job-openings)\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Contact](https://www.biofrontera-us.com/contact)\n  * [IR Menu](#)Open menu\n    * [Investors](https://investors.biofrontera-us.com/)\n    * [Corporate Information](https://investors.biofrontera-us.com/corporate-information/)\n    * [News & Events](https://investors.biofrontera-us.com/news-events/)\n    * [Stock Information](https://investors.biofrontera-us.com/stock-information/)\n    * [Financial Reports](https://investors.biofrontera-us.com/financial-reports/)\n    * [SEC Filings](https://investors.biofrontera-us.com/sec-filings/)\n    * [Contacts and Email Alerts](https://investors.biofrontera-us.com/contacts-and-email-alerts/)\n\n\n\n[ ![](https://investors.biofrontera-us.com/wp-content/uploads/2021/07/logo-biofrontera.png) ](https://www.biofrontera-us.com/)\n\nX\n\n# SEC Filings\n\n## SEC Filings\n\n## Archive Financial Reports \n\nThere are no items to display at this time.\n\nFinancial reports 2021\n\n[Annual report 2021](#)\n\n[Quarterly report Q3 2021](#)\n\n[Half-Year report 2021](#)\n\n[Quarterly report Q1 2021](#)\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nInvestor Relationsir@bfinc.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\n![logo-lgt-white](https://investors.biofrontera-us.com/wp-content/uploads/elementor/thumbs/logo-lgt-white-peg8pj14lqgfmpirltknyotvhn6v9niva99agihb3q.png)\n\nBiofrontera is a highly innovative specialty dermatology company, focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care. \n\n120 Presidential Way, Suite 330Woburn, MA 01801[ 1-781-245-1325](tel:1-781-245-1325)info-us@biofrontera.com\n\nINVESTOR RELATIONS CONTACTPamela Keck [+49-214-87632-92 ](tel:+49-214-87632-92)us-ir@biofrontera.com \n\n  * [ ](https://www.linkedin.com/company/biofrontera-inc)\n\n\n\nÂ© Copyright 2021, Biofrontera Corp. All rights reserved.\n"
        }
      ]
    }
  ]
}